AB0773 Serum VEGF level may be have a role in the evaluation of treatment response and disease activity during TNFi therapy in patients with AxSpA

Autor: M. Gulec Yazir, E. Durak Ediboglu, G. Alp, H. Cinakli, İ. Kurut Aysin, E. Erpek, E. Otman Akat, S. Gucenmez, M. Ozmen, S. Ketenci, O. Bayindir, D. Solmaz, S. Akar
Rok vydání: 2022
Předmět:
Zdroj: Annals of the Rheumatic Diseases. 81:1512.2-1513
ISSN: 1468-2060
0003-4967
Popis: BackgroundPatient reported outcomes (BASDAI and BASFI) are used to evaluate disease activity in axial spondylarthritis (axSpA), however, apart from C-reactive protein (CRP) there are no widely used serum biomarkers to assess disease activity and treatment responce.ObjectivesIn this study, we aimed to evaluate the relationship between serum biomarkers (serum leptin, VEGF, MMP-3) and disease activity as well as the changes of those biomarker levels during TNFi treatment.MethodsPatients with axSpA who put on their first TNFi and had serum samples at baseline and 6th month of therapy were included in the analysis The demographic, clinical and laboratory characteristics disease activity and function parameters (BASDAI, BASFI, ASDAS-CRP, serum CRP levels) at baseline and 6th months were recorded. Levels of serum leptin, VEGF and MMP-3 were studied by ELISA method. The relationship between serum biomarkers and disease activity scales in addition CRP levels were tested by correlation analysis. The factors affecting the change in seruml biomarkers level in 6th month were also analyzed by GEE which is a longitudanal analysis method.ResultsA total of 74 patients (mean age (SD) 48.7 (12.8) years, 54.1% male, 68.9% with AS) were included in this study. Baseline median BASDAI scores (IQR) were 5.8 (2.4), ASDAS scores (IQR) 3.7 (1.5) and median CRP levels (IQR) 12 (23). Disease activity parameters (BASDAI, BASFI, ASDAS-CRP) were significantly decreased at 6th month of therapy (pth month of TNFi treatment (pTable 1.The factors associated with serum VEGF levels longitudinallyUnivariate analizBASDAİ+CRP ModelASDAS -CRP ModelB (%95 CI)pB (%95 CI)pB (%95 CI)pHip involvement181.74 (12.71- 350.77)0.035357.04(112.35- 601.73)0.04338.36 (102.40-574.3)0.005Duration of delay in diagnosis-6.91 (-14.05- 0.24)0.058-13.93 (-24.56 to -3.31)0.01-14.36 (-24.68 to -4.03)0.006Gender-216.88 (-390.6 to -43.2)0.014-154.23 (-336.94- 28.48)0.09-162.6(-336.70- 11.4)0.006HLA-B27 positivity-233.4 (-440.67 to -26.11)0.027-135.78(-326.08- 54.52)0.16-126.54(-309.2- 56.1)0.17BASDAI4.12 (1.06- 7.18)0.0085.60 (2.16- 9.05)0.001ASDAS-CRP110.04 (58.18- 161.88)132.31(74.70- 189.92)Serum CRP level5.86 (1.02- 10.7)0.0184.09 (-0.99- 9.183)0.11ConclusionTNFi treatment is not only effectively control disease activity but also cause significant decrease in serum VEGF levels in patients with axSpA. Considering the role of VEGF in radiographic progression it could be a promising biomarker in axSpADisclosure of InterestsNone declared
Databáze: OpenAIRE
Externí odkaz: